1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow allantoicase: new trials by email Literature Review of allantoicase trials Research Report on allantoicase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid, Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid - Prostate Cancer, Ovarian Cancer | Phase 2 | Completed | Bayer | 150 | 2008-08-01 | 2014-10-28 |
| Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue ALC and Placebo - Breast Cancer | Phase 2 | Terminated | Sigma-Tau Research, Inc. | 27 | 2007-03-01 | 2012-08-28 |
Breast Neoplasms (1) · Ovarian Neoplasms (1) · Peripheral Nervous System Diseases (1) · Prostatic Neoplasms (1)
Bayer (1) · Sigma-Tau Research, Inc. (1)
Belgium (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · United Kingdom (1) · United States (1)
2008 (1)